Biblio Discovery — Demo Discovery Service

6 results for "Wustner, Jason"

Showing 1–6 · 1.14 seconds · RSS

  1. Journal Article Full text

    Population pharmacokinetics and exposure–response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection

    Gupta, Anubha; Hussein, Ziad; Hassan, Raffit et al.

    Cancer Chemother Pharmacol · 2016 · English · PubMed Central

    PURPOSE: To characterize amatuximab pharmacokinetics (PK) and the relationship of amatuximab exposure with response in patients with unresectable malignant pleural mesothelioma (MPM) receiving amatuximab with pemetrexed and cisplatin. METHODS: A nonlinear mixed effects PK model was built using data…

  2. Journal Article Full text

    Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer

    Farrell, Colm; Schweizer, Charles; Wustner, Jason et al.

    Cancer Chemother Pharmacol · 2012 · English · PubMed Central

    PURPOSE: The purpose of this analysis was to develop a population pharmacokinetic model for farletuzumab, a humanized immunoglobulin (Ig)G(1) monoclonal antibody (mAb) to the folate receptor alpha, which is a receptor over-expressed in ovarian cancer, but largely absent from normal tissue. METHODS…

  3. Journal Article Full text

    A First-in-Human Phase I Study of MORAb-004, a Monoclonal Antibody to Endosialin in Patients with Advanced Solid Tumors

    Diaz, Luis A.; Coughlin, Christina M.; C.Weil, Susan et al.

    Clin Cancer Res · 2014 · English · PubMed Central

    PURPOSE: Endosialin (TEM-1, CD248) is a protein expressed on the surface of activated mesenchymal cells, including certain subsets of tumors. Preclinical models suppressing endosialin function have shown antitumor activity. A humanized monoclonal antibody, MORAb-004, was engineered to target…

  4. Journal Article Full text

    Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies

    Lopez, Juanita S.; Milhem, Mohammed; Butler, Marcus O. et al.

    Cell Rep Med · 2025 · English · PubMed Central

    IMCnyeso, an immune mobilizing monoclonal T cell receptor against cancer (ImmTAC) bispecific (New York esophageal squamous cell carcinoma [NY-ESO]×CD3) T cell engager, targets an NY-ESO-1/L-antigen family member-1 isoform A (LAGE-1A) peptide presented by histocompatibility leukocyte antigen…

  5. Journal Article Full text

    Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature

    Rybinski, Katherine; Imtiyaz, Hongxia Z.; Mittica, Barrie et al.

    Oncotarget · 2015 · English · PubMed Central

    Over-expression of endosialin/CD248 (herein referred to as CD248) has been associated with increased tumor microvasculature in various tissue origins which makes it an attractive anti-angiogenic target. In an effort to target CD248, we have generated a human CD248 knock-in mouse line and MORAb-004…

  6. Journal Article Full text

    Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trial

    Vandekerckhove, Linos; Fox, Julie; Mora-Peris, Borja et al.

    Nat Commun · 2026 · English · PubMed Central

    HIV persistence in reservoirs despite antiretroviral therapy (ART) is a barrier to a permanent cure. We present the affinity-enhanced TCR bispecific IMC-M113V as a potential therapeutic for targeted HIV reservoir elimination. Preclinical studies demonstrate that IMC-M113V redirects T cells towards…